Korro Bio, Inc.
A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.
KRRO | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 60 FIRST STREET, 2141 CAMBRIDGE
- Website:
- https://www.korrobio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Korro Bio, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes a new class of genetic medicines based on RNA editing. The company's proprietary platform, Oligonucleotide Promoted Editing of RNA (OPERA®), harnesses the body's natural ADAR (Adenosine Deaminase Acting on RNA) editing process to make precise, single-base changes to RNA. This approach aims to modulate protein function by repairing mutations or altering protein activity to treat a broad range of rare and highly prevalent diseases, with an initial focus on conditions such as Alpha-1 Antitrypsin Deficiency (AATD).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Korro Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Korro Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Korro Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
